Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

iCAD

This article was originally published in The Gray Sheet

Executive Summary

Company plans to file a 510(k) for the VeraLook computer-aided detection system for computed tomography (CT) colonography late this month or in April. iCAD previewed the investigational system at the European Society of Radiology annual meeting in Vienna March 6-10. The device can automatically identify polyps and streamline the image reading process, firm says. Data from a National Cancer Institute study published last fall supports using CT colonography, a non-invasive alternative to colonoscopy, as a screening option in cancers 10 mm or larger, but use of the technology may be limited by its cost (1"The Gray Sheet" Sept. 22, 2008, p. 21)

You may also be interested in...



CT Colonoscopy Gets Further Support From NCI Study In NEJM

Results of a major study sponsored by the National Cancer Institute and the American College of Radiology Imaging Network provide more support for computed tomographic colonography as an alternative to visual colonoscopy for colorectal cancer screening

Volume-Based Purchasing Looms Larger In Post-Coronavirus China

China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.

Deals In Depth: February 2020

Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.

Topics

UsernamePublicRestriction

Register

MT027188

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel